NASDAQ: KALA
Kala Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for KALA

Based on 2 analysts offering 12 month price targets for Kala Bio Inc

Min Forecast
$12.00+43.03%
Avg Forecast
$13.50+60.91%
Max Forecast
$15.00+78.78%

Should I buy or sell KALA stock?

Based on 2 analysts offering ratings for Kala Bio Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KALA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates KALA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their KALA stock forecasts and price targets.

KALA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-02
lockedlocked$00.00+00.00%2025-05-23

1 of 1

Forecast return on equity

Is KALA forecast to generate an efficient return?

Company
N/A
Industry
31.11%
Market
-48.11%

Forecast return on assets

Is KALA forecast to generate an efficient return on assets?

Company
N/A
Industry
14.75%

KALA earnings per share forecast

What is KALA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$5.32
Avg 2 year Forecast
-$3.35

KALA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
KALA$8.39$13.50+60.91%Buy
BGM$7.81N/AN/A
DRRX$1.88N/AN/A
CPIX$3.08N/AN/A
QNTM$18.03N/AN/A

Kala Bio Stock Forecast FAQ

Is Kala Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KALA) stock is to Buy KALA stock.

Out of 2 analysts, 0 (0%) are recommending KALA as a Strong Buy, 2 (100%) are recommending KALA as a Buy, 0 (0%) are recommending KALA as a Hold, 0 (0%) are recommending KALA as a Sell, and 0 (0%) are recommending KALA as a Strong Sell.

If you're new to stock investing, here's how to buy Kala Bio stock.

What is KALA's earnings growth forecast for 2025-2026?

(NASDAQ: KALA) Kala Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 23.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Kala Bio's earnings in 2025 is -$35,651,000.On average, 3 Wall Street analysts forecast KALA's earnings for 2025 to be -$34,348,050, with the lowest KALA earnings forecast at -$38,456,292, and the highest KALA earnings forecast at -$31,036,034.

In 2026, KALA is forecast to generate -$21,583,271 in earnings, with the lowest earnings forecast at -$25,164,352 and the highest earnings forecast at -$18,002,190.

What is KALA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KALA) forecast ROE is N/A, which is considered weak.

What is KALA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year KALA price target, the average KALA price target is $13.50, with the highest KALA stock price forecast at $15.00 and the lowest KALA stock price forecast at $12.00.

On average, Wall Street analysts predict that Kala Bio's share price could reach $13.50 by Jun 2, 2026. The average Kala Bio stock price prediction forecasts a potential upside of 60.91% from the current KALA share price of $8.39.

What is KALA's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: KALA) Kala Bio's current Earnings Per Share (EPS) is -$7.97. On average, analysts forecast that KALA's EPS will be -$5.32 for 2025, with the lowest EPS forecast at -$5.96, and the highest EPS forecast at -$4.81. In 2026, KALA's EPS is forecast to hit -$3.35 (min: -$3.90, max: -$2.79).

What is KALA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KALA) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.75%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.